What is Xenon Pharmaceuticals Inc Annual Net Profit?

Xenon Pharmaceuticals Inc Annual Net Profit fell 28.48% in the last year to $234.33 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

What is Xenon Pharmaceuticals Inc Price to Earning Ratio?

Xenon Pharmaceuticals Inc Price to Earning Ratio is -11.91, which is negative.

What is Xenon Pharmaceuticals Inc Stock Price?

Xenon Pharmaceuticals Inc Stock Price fell 17.16% and underperformed its sector by 27.06% in the past year.

What is Xenon Pharmaceuticals Inc Quarterly Net profit?

Xenon Pharmaceuticals Inc Quarterly Net profit fell 46.81% YoY to $65.68 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

What is Xenon Pharmaceuticals Inc Debt to Equity Ratio?

Xenon Pharmaceuticals Inc Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Xenon Pharmaceuticals Inc Return on Equity(ROE)?

Xenon Pharmaceuticals Inc Return on Equity(ROE) for the last financial year was -27.85%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Xenon Pharmaceuticals Inc Mutual Fund Holding?

Xenon Pharmaceuticals Inc Mutual Fund Holding increased by 0.24% in the last quarter to 58.65.

What is Xenon Pharmaceuticals Inc Promoter Share Holding?

Xenon Pharmaceuticals Inc Promoter Share Holding stayed the same in the most recent quarter at 0.34%.

What is Xenon Pharmaceuticals Inc Institutional Holding?

Xenon Pharmaceuticals Inc Institutional Holding increased by 0.88% in the last quarter to 100.83.

How is the Xenon Pharmaceuticals Inc today?

The Xenon Pharmaceuticals Inc today is trading in the green, up by 3.14% at 36.45.

How has Xenon Pharmaceuticals Inc performed historically?

The Xenon Pharmaceuticals Inc is currently trading up 3.14% on an intraday basis in the past week the index rose 3.20%. The index has been down -4.43% in the past quarter and fell -17.16% in the past year. You can view this in the overview section.

Xenon Pharmaceuticals Inc XNAS: XENE

Xenon Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

Name: Xenon Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Xenon Pharmaceuticals Inc
Rating: 1.13491675
Author: Trendlyne DVM scores

Download real time

36.45 1.11 (3.14%)

52W Low on Feb 28, 2025

454.3K XNAS Volume

XNAS 24 Mar, 2025 5:30 PM (EDT)

Xenon Pharmaceuticals Inc Key Metrics

My Metrics

Default

Market Capitalization High in industry Unavailable in chosen country	2,790
PE TTM Negative PE TTM Unavailable in chosen country	-11.9
PEG TTM High in industry Unavailable in chosen country	0.4
Price to Book Below industry Median Unavailable in chosen country	3.7
Institutional holding current Qtr % High in industry Unavailable in chosen country	100.8
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-46.8
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-28.5
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-11.7
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-27.8
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-26.6

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

5.2 / 100

Technically Neutral

40.2 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Xenon Pharmaceuticals Inc Stock Price Analysis

Day Price Range 3.1% 1 Day return Unavailable in chosen country	36.4 (LTP) 35.236.5 LowHigh
Week Price Range 3.2% 1 Week return Unavailable in chosen country	36.4 (LTP) 34.236.5 LowHigh
Month Price Range -8.3% 1 Month return Unavailable in chosen country	36.4 (LTP) 33.340 LowHigh
52 Week Price Range -17.2% 1 Year return Unavailable in chosen country	36.4 (LTP) 33.346 LowHigh

View full Share Price History

Xenon Pharmaceuticals Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Miss

Xenon Pharmaceuticals Inc's Revenue was lower than average estimate 2 times in past 2 years

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Xenon Pharmaceuticals Inc Stock Analysis

Xenon Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

Xenon Pharmaceuticals Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$234.33 M	28.48%	negative	Annual Net Profit fell 28.48% in the last year to $234.33 M. Its sector's average net profit growth for the last fiscal year was -32.46%.
Price to Earning Ratio	-11.91	-	negative	Price to Earning Ratio is -11.91, which is negative.
Stock Price	$36.45	-17.16%	negative	Stock Price fell 17.16% and underperformed its sector by 27.06% in the past year.
Quarterly Net profit	$65.68 M	46.81%	negative	Quarterly Net profit fell 46.81% YoY to $65.68 M. Its sector's average net profit growth YoY for the quarter was -47.25%.
Debt to Equity Ratio	0.01	-	positive	Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-27.85 %	-27.85%	negative	Return on Equity(ROE) for the last financial year was -27.85%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	58.65 %	0.24%	positive	Mutual Fund Holding increased by 0.24% in the last quarter to 58.65.
Promoter Share Holding	0.34 %	0%	neutral	Promoter Share Holding stayed the same in the most recent quarter at 0.34%.
Institutional Holding	100.83 %	0.88%	positive	Institutional Holding increased by 0.88% in the last quarter to 100.83.

VIEW LESS

Loading data..

Xenon Pharmaceuticals Inc - Company Profile

What does Xenon Pharmaceuticals Inc do?

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Xenon Pharmaceuticals Inc Management structure

All Gross Remunerations are in USD

Dr. Christopher E. Von Seggern, PhD

Chief Commercial Officer

2025

Gross Remuneration

2024

Gross Remuneration

Year

Xenon Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

52W Low on Feb 28, 2025

Xenon Pharmaceuticals Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Xenon Pharmaceuticals Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Xenon Pharmaceuticals Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Xenon Pharmaceuticals Inc's Revenue was lower than average estimate 2 times in past 2 years

Xenon Pharmaceuticals Inc Stock Analysis

Xenon Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 28.48% in the last year to $234.33 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio is -11.91, which is negative.

Stock Price fell 17.16% and underperformed its sector by 27.06% in the past year.

Quarterly Net profit fell 46.81% YoY to $65.68 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -27.85%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.24% in the last quarter to 58.65.

Promoter Share Holding stayed the same in the most recent quarter at 0.34%.

Institutional Holding increased by 0.88% in the last quarter to 100.83.

Xenon Pharmaceuticals Inc - Company Profile

What does Xenon Pharmaceuticals Inc do?

Xenon Pharmaceuticals Inc Management structure

Dr. Christopher E. Von Seggern, PhD

Chief Commercial Officer

Xenon Pharmaceuticals Inc Board of directors

Mr. Patrick C. Machado, J.D.

Independent Director

Mr. Gary Patou, M.D.

Independent Director

Mr. Justin David Gover

Independent Director

Mr. Ian C. Mortimer

Director, Chief Executive Officer and President

Ms. Dawn A. Svoronos

Chairman of the Board

Mr. Steven Gannon

Independent Director

Xenon Pharmaceuticals Inc FAQ

How is Xenon Pharmaceuticals Inc today?

Xenon Pharmaceuticals Inc today is trading in the green, and is up by 3.14% at 36.45.

How has Xenon Pharmaceuticals Inc performed historically?

Xenon Pharmaceuticals Inc is currently trading up 3.14% on an intraday basis. In the past week the stock rose 3.20%. stock has been down -4.43% in the past quarter and fell -17.16% in the past year. You can view this in the overview section.